Internal Medicine, Hematology & Oncology · Oklahoma City, OK
NPI
1124069364
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
5915 W Memorial Rd, Suite 200
Oklahoma City, OK, 73142
Phone (405) 773-6400
Groups this clinician bills Medicare through
Medicare paid, 2024
$97K
2,116 services
Medicare patients, 2024
475
Average age 75
Drug cost, 2024
$6.1M
2,064 prescriptions
Company payments, 2025
$431
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Johnny R McMinn was code 99214 (office e&m - established), 930 times for 379 patients. In total Johnny R McMinn billed 2,116 services in 11 codes, and Medicare paid $97K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-06-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 930 | 379 | $63.61 | $59K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 862 | 371 | $11.63 | $10K |
| 99232 Hospital E&M - Subsequent | Facility | 173 | 56 | $57.98 | $10K |
| 99205 Office E&M - New | Office | 84 | 84 | $130.89 | $11K |
| 99223 Hospital E&M - Initial | Facility | 42 | 41 | $117.60 | $4,939 |
By year: 2022 $83K for 1,163 services; 2023 $79K for 1,102 services; 2024 $97K for 2,116 services.
Medicare prescription drug claims, 2024
In 2024, the drug Johnny R McMinn prescribed most often to Medicare patients was Oxycodone-Acetaminophen (Oxycodone Hcl/Acetaminophen), with 91 prescriptions and refills. In total Johnny R McMinn wrote 2,064 Medicare prescriptions that cost $6.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 91 | 91 | 17 | $2,300 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 85 | 85 | 36 | $2,797 |
| Hydroxyurea Generic | 73 | 125 | 13 | $2,059 |
| Imbruvica Ibrutinib | 73 | 73 | Under 11 | $1.1M |
| Potassium Chloride Generic | 72 | 114 | 17 | $806 |
| Oxycodone Hcl Generic | 67 | 67 | 23 | $1,660 |
| Eliquis Apixaban | 65 | 70 | 13 | $41K |
| Revlimid Lenalidomide | 63 | 63 | Under 11 | $1.2M |
| Xtandi Enzalutamide | 58 | 58 | Under 11 | $810K |
| Anastrozole Generic | 56 | 128 | 15 | $677 |
| Diphenhydramine Hcl Generic | 56 | 56 | Under 11 | $1,752 |
| Calquence Acalabrutinib Maleate | 56 | 56 | Under 11 | $812K |
| Famotidine Famotidine/Pf | 52 | 52 | Under 11 | $339 |
| Ondansetron Hcl Ondansetron Hcl/Pf | 52 | 52 | Under 11 | $1,614 |
| Alprazolam Generic | 51 | 57 | Under 11 | $442 |
Brand drugs: 528 claims; generic drugs: 1,536 claims; opioid claims: 314.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Johnny R McMinn $431 ($431 in general payments such as food, travel and fees) from 10 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $150.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 4 | $150 |
| Janssen Biotech, Inc. JNJ | 2 | $53.9 |
| E.R. Squibb & Sons, L.L.C. BMY | 2 | $41.24 |
| BeOne Medicines USA, Inc. ONC | 2 | $36.13 |
| Medtronic, Inc. MDT | 1 | $35.15 |
| Genzyme Corporation SNY | 1 | $30.63 |
| Geron Corporation GERN | 1 | $23.52 |
| Celgene Corporation BMY | 1 | $20.91 |
| Stemline Therapeutics Inc. | 1 | $20.81 |
| Alexion Pharmaceuticals, Inc. AZN | 1 | $19.61 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.